Cancer Cachexia Pipeline Shows Promise with 20+ Therapies in Development Across Multiple Companies
核心洞察
DelveInsight's 2025 pipeline report reveals 18+ active companies developing 20+ cancer cachexia therapies, addressing a critical unmet need in oncology care.
Key developments include Endevica Bio's TCMCB07 entering Phase II trials and CSPC's JMT203 receiving FDA approval for US clinical studies.
Cancer cachexia affects up to 87% of pancreatic and gastric cancer patients and accounts for approximately 22% of cancer-related deaths.
The cancer cachexia therapeutic pipeline is experiencing unprecedented growth, with over 18 companies actively developing more than 20 experimental treatments for this debilitating condition that affects millions of cancer patients worldwide. According to DelveInsight's comprehensive 2025 pipeline analysis, the field is gaining momentum driven by rising global cancer burden, increased awareness of disease mechanisms, and regulatory support through orphan drug designations.
Robust Pipeline Activity Addresses Critical Unmet Need
Cancer cachexia represents one of oncology's most challenging complications, characterized as a wasting syndrome that leads to significant loss of skeletal muscle and fat tissue. The condition severely impacts patient quality of life and is linked to poor chemotherapy response and reduced survival rates. As reported by Warren, cancer cachexia accounts for approximately 22% of cancer-related deaths, making it a critical target for therapeutic intervention.
The disease burden varies significantly by cancer type, affecting up to 87% of patients with pancreatic and gastric cancers, while impacting about 40% of those with breast cancer, sarcoma, leukemia, or Hodgkin lymphoma. This widespread prevalence, combined with limited approved treatment options, has created substantial demand for innovative therapies that can address weight loss, muscle wasting, and appetite loss.
Key Clinical Developments Drive Pipeline Progress
Several major pharmaceutical companies have achieved significant milestones in recent months. In April 2025, Endevica Bio announced the first patient dosing in a Phase II trial for TCMCB07 (B07), an experimental drug designed to prevent weight loss in cancer patients undergoing chemotherapy. The trial's primary endpoint focuses on preventing weight loss that can lead to cachexia, with patients receiving B07 as they begin chemotherapy and during initial treatment rounds.
CSPC Pharmaceutical Group Limited achieved a regulatory milestone in April 2025 when the US Food and Drug Administration approved clinical trials for JMT203, an antibody drug independently developed by subsidiary Shanghai JMT-BIO Technology Co., Ltd (搜索). The therapy previously received approval from China's National Medical Products Administration in June 2023 and is currently undergoing clinical trials in China.
GenFleet Therapeutics (搜索) advanced its GFS202A program in March 2025, receiving approval from China's National Medical Products Administration for an open-label, multi-center Phase I study treating cancer patients with precachexia and cachexia. The dual-mechanism therapy targets both growth differentiation factor 15 and interleukin 6 pathways.
Diverse Therapeutic Approaches Target Multiple Pathways
The pipeline demonstrates remarkable diversity in therapeutic approaches and mechanisms of action. Leading candidates include:
ACM-001.1 from Actimed Therapeutics (搜索), a Phase II oral therapy combining 5-HT1A serotonin receptor antagonists with beta adrenergic receptor modulators.
Ponsegromab from Pfizer, a Phase II subcutaneous treatment targeting growth differentiation factor 15 inhibition.
FDY-8801 from Faraday Pharmaceuticals (搜索), a Phase II beta-adrenergic receptor antagonist.
TCMCB07 from Endevica Bio, targeting melanocortin type 3 and 4 receptors through subcutaneous administration.
GFS202A from GenFleet Therapeutics (搜索), combining growth differentiation factor 15 and interleukin 6 inhibition via intravenous delivery.
Funding and Partnership Activity Accelerates Development
Investment activity has intensified across the sector. Tensegrity Pharma (搜索) completed a 150 million yen seed funding round in January 2025 from Mitsubishi UFJ Capital Limited, bringing total raised funds to 650 million yen including previous investment from Newton Biocapital Co. The company plans to accelerate development of TSP-101 (搜索) for cachexia treatment.
Strategic partnerships are also emerging, with Meta Fines (搜索) announcing a licensing agreement with BMI Korea (搜索) for ASCA101CC (搜索) in February 2024. Under the agreement, BMI Korea will co-own global technology transfer rights and hold licensing rights for Korea and Southeast Asian markets.
Clinical Challenge Drives Innovation
Cancer cachexia diagnosis typically involves observing clinical signs including unintended weight loss greater than 5% over six months, reduced appetite, declining muscle strength, and deterioration in overall functional capacity. Laboratory tests may reveal anemia, increased inflammatory markers, and metabolic imbalances, while imaging can show tumor burden and complications.
Current management relies on a multidisciplinary approach involving symptom control, nutritional interventions, physical rehabilitation, and treatment of underlying cancer. However, effective management requires personalized, holistic strategies targeting muscle preservation, improving physical condition, and boosting patients' ability to tolerate cancer therapies.
Market Dynamics Support Continued Growth
The cancer cachexia therapeutics market is gaining traction due to multiple converging factors. The rising global cancer burden, combined with high prevalence of cachexia in advanced-stage patients and limited approved treatments, creates substantial market opportunity. Increased awareness, deeper understanding of disease mechanisms, and regulatory support through orphan drug designations are driving research and development investments.
An aging population and the shift toward holistic oncology care are expected to fuel sustained market growth. The pipeline assessment reveals therapeutic candidates segmented across discovery, pre-clinical, Phase I, Phase II, and Phase III stages, with diverse product types including monotherapies, combinations, and various molecular approaches including monoclonal antibodies, peptides, polymers, small molecules, and gene therapies.